Sulfur mustard corneal injury is associated with alterations in the epithelial basement membrane and stromal extracellular matrix.
Basement membrane
Cornea
Perlecan
Sulfur mustard
Tenacin-C
Journal
Experimental and molecular pathology
ISSN: 1096-0945
Titre abrégé: Exp Mol Pathol
Pays: Netherlands
ID NLM: 0370711
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
11
03
2022
revised:
20
05
2022
accepted:
29
06
2022
pubmed:
8
7
2022
medline:
26
10
2022
entrez:
7
7
2022
Statut:
ppublish
Résumé
Sulfur mustard (SM; bis(2-chloroethyl) sulfide) is a highly reactive bifunctional alkylating agent synthesized for chemical warfare. The eyes are particularly sensitive to SM where it causes irritation, pain, photophobia, and blepharitis, depending on the dose and duration of exposure. In these studies, we examined the effects of SM vapor on the corneas of New Zealand white male rabbits. Edema and hazing of the cornea, signs of acute injury, were observed within one day of exposure to SM, followed by neovascularization, a sign of chronic or late phase pathology, which persisted for at least 28 days. Significant epithelial-stromal separation ranging from ~8-17% of the epithelial surface was observed. In the stroma, there was a marked increase in CD45
Identifiants
pubmed: 35798063
pii: S0014-4800(22)00070-3
doi: 10.1016/j.yexmp.2022.104807
pmc: PMC10044521
mid: NIHMS1871581
pii:
doi:
Substances chimiques
Mustard Gas
T8KEC9FH9P
Heparan Sulfate Proteoglycans
0
Tenascin
0
Fibronectins
0
Alkylating Agents
0
Sulfides
0
Collagen
9007-34-5
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
104807Subventions
Organisme : NIEHS NIH HHS
ID : P30 ES005022
Pays : United States
Organisme : NIAMS NIH HHS
ID : U54 AR055073
Pays : United States
Informations de copyright
Copyright © 2022. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors have no conflict of interest for the subject matter of this paper.
Références
Cutan Ocul Toxicol. 2010 Dec;29(4):269-77
pubmed: 20868209
J Appl Toxicol. 2000 Dec;20 Suppl 1:S173-5
pubmed: 11428631
Cornea. 2016 Feb;35(2):257-66
pubmed: 26555588
J Cell Biol. 1986 Jul;103(1):49-62
pubmed: 2424919
Acta Ophthalmol Suppl (1985). 1985;173:30-1
pubmed: 3002096
Front Immunol. 2021 Apr 07;12:667830
pubmed: 33897716
Differentiation. 1987;34(1):60-7
pubmed: 2440750
Ann N Y Acad Sci. 2016 Jun;1374(1):132-43
pubmed: 27310673
Methods Mol Biol. 2020;2145:17-27
pubmed: 32542597
Ann N Y Acad Sci. 2016 Jun;1374(1):193-201
pubmed: 27327041
Epithelial Cell Biol. 1993 Jul;2(3):120-5
pubmed: 7688259
Toxicol Lett. 2021 Jun 1;343:21-27
pubmed: 33600921
Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):4044-4053
pubmed: 30098200
Semin Cell Dev Biol. 2008 Apr;19(2):82-93
pubmed: 17997336
Exp Eye Res. 2014 Dec;129:151-60
pubmed: 25281830
Am J Ophthalmol. 1946 Aug;29:929-38
pubmed: 20994632
J Opt Soc Am. 1976 Apr;66(4):342
pubmed: 1262983
Graefes Arch Clin Exp Ophthalmol. 1998 Jul;236(7):553-8
pubmed: 9672803
Sci Rep. 2019 Oct 3;9(1):14272
pubmed: 31582785
Brain Res Bull. 2010 Feb 15;81(2-3):211-8
pubmed: 19720116
Lab Invest. 2021 Jun;101(6):690-700
pubmed: 33782532
Cutan Ocul Toxicol. 2013 Jun;32(2):115-23
pubmed: 23106194
Curr Eye Res. 2011 Dec;36(12):1098-107
pubmed: 21988526
Invest Ophthalmol Vis Sci. 2013 Oct 15;54(10):6735-44
pubmed: 24045986
Exp Mol Pathol. 2019 Oct;110:104275
pubmed: 31233733
Hum Mol Genet. 2016 Mar 15;25(6):1176-91
pubmed: 26758872
Hum Genet. 2009 May;125(4):355-73
pubmed: 19247691
Optom Vis Sci. 2010 Apr;87(4):E239-54
pubmed: 20142793
Cutan Ocul Toxicol. 2013 Jun;32(2):140-9
pubmed: 23106216
J Cataract Refract Surg. 2003 Feb;29(2):354-60
pubmed: 12648649
Stem Cells Dev. 2014 Jun 15;23(12):1340-54
pubmed: 24499373
PLoS One. 2021 Oct 12;16(10):e0258503
pubmed: 34637469
Graefes Arch Clin Exp Ophthalmol. 1997 Apr;235(4):222-9
pubmed: 9143890
Toxicol Lett. 2021 Oct 1;349:124-133
pubmed: 34153409
Curr Pharm Des. 2017;23(11):1589-1597
pubmed: 27774903
Cells. 2021 Mar 20;10(3):
pubmed: 33804633
Cornea. 2013 Nov;32 Suppl 1:S43-5
pubmed: 24104933
Ocul Surf. 2013 Jan;11(1):12-5
pubmed: 23321354
Chem Biol Interact. 2013 Dec 5;206(3):512-22
pubmed: 23816402
Cutan Ocul Toxicol. 2016 Dec;35(4):319-28
pubmed: 27002633
Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2381-9
pubmed: 16723447
Curr Eye Res. 2014 Aug;39(8):803-12
pubmed: 24502433
Immunopharmacol Immunotoxicol. 2021 Aug;43(4):452-460
pubmed: 34167418
Exp Eye Res. 2020 May;194:108002
pubmed: 32179076
Cornea. 2020 May;39(5):640-648
pubmed: 32044824
Exp Eye Res. 2010 Sep;91(3):326-35
pubmed: 20599432
Exp Eye Res. 2006 Nov;83(5):1063-73
pubmed: 16822507
Invest Ophthalmol Vis Sci. 1990 Sep;31(9):1779-88
pubmed: 2170294
PLoS One. 2012;7(8):e42837
pubmed: 22900056
Cornea. 2010 Aug;29(8):889-94
pubmed: 20489576
J Ocul Pharmacol Ther. 2010 Oct;26(5):407-19
pubmed: 20925577
Drug Chem Toxicol. 2019 May;42(3):231-242
pubmed: 29171299
Ocul Surf. 2011 Jul;9(3):163-78
pubmed: 21791191
Cornea. 2004 Mar;23(2):165-71
pubmed: 15075886
Invest Ophthalmol Vis Sci. 2016 Apr;57(4):1687-98
pubmed: 27058125
Curr Eye Res. 2014 May;39(5):439-50
pubmed: 24215293
J Cell Biochem. 2017 Nov;118(11):3549-3560
pubmed: 28106291
Toxicology. 2009 Sep 1;263(1):59-69
pubmed: 19061933
Transl Vis Sci Technol. 2020 Nov 02;9(12):6
pubmed: 33200047
Toxicol Appl Pharmacol. 2022 Feb 15;437:115904
pubmed: 35108561
Ann N Y Acad Sci. 2010 Apr;1194:72-80
pubmed: 20536452
Invest Ophthalmol Vis Sci. 1991 Dec;32(13):3221-37
pubmed: 1660857
Exp Eye Res. 2020 Nov;200:108206
pubmed: 32882212
Eye Contact Lens. 2019 Mar;45(2):112-116
pubmed: 30005052
Ophthalmology. 2011 Jul;118(7):1272-81
pubmed: 21397949
Ocul Surf. 2021 Jan;19:290-306
pubmed: 33127599
Cornea. 2013 Apr;32(4):e44-50
pubmed: 23132440
PLoS One. 2022 Jan 10;17(1):e0262046
pubmed: 35007294
Prog Retin Eye Res. 2015 Nov;49:1-16
pubmed: 26145225
Mol Vis. 2008 Sep 15;14:1713-8
pubmed: 18806880
J Appl Toxicol. 2010 Oct;30(7):627-43
pubmed: 20836142
J Histochem Cytochem. 2004 Oct;52(10):1341-50
pubmed: 15385580
Exp Eye Res. 2016 Jan;142:110-8
pubmed: 26675407
Exp Eye Res. 2021 Mar;204:108457
pubmed: 33493471
Toxicol Appl Pharmacol. 2012 Oct 1;264(1):23-31
pubmed: 22841772
J Appl Toxicol. 2000 Dec;20 Suppl 1:S109-14
pubmed: 11428620
Trans Am Ophthalmol Soc. 2006;104:264-302
pubmed: 17471348
Lab Invest. 2013 Feb;93(2):207-17
pubmed: 23207449
Biochim Biophys Acta Proteins Proteom. 2017 Nov;1865(11 Pt A):1445-1454
pubmed: 28882529
Toxicol Appl Pharmacol. 2013 Oct 15;272(2):345-55
pubmed: 23845594
Toxicology. 2009 Sep 1;263(1):3-8
pubmed: 19482056
Exp Eye Res. 2018 Dec;177:145-152
pubmed: 30114412
Anat Rec (Hoboken). 2021 Sep;304(9):1974-1983
pubmed: 33554453
Exp Mol Pathol. 2021 Aug;121:104656
pubmed: 34081961
Mol Vis. 2010 Jul 01;16:1194-205
pubmed: 20664686
Exp Eye Res. 2004 Mar;78(3):553-60
pubmed: 15106935
Biomaterials. 2010 Feb;31(5):964-74
pubmed: 19853296
Int Immunopharmacol. 2019 Dec;77:105844
pubmed: 31669888
Exp Eye Res. 2010 Jun;90(6):771-9
pubmed: 20346358
Invest Ophthalmol Vis Sci. 2004 Nov;45(11):4010-5
pubmed: 15505050
Ann N Y Acad Sci. 2016 Aug;1378(1):158-165
pubmed: 27737494
Toxicol Lett. 2021 Apr 1;340:58-66
pubmed: 33440228